Cargando…

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Cerezo-Martin, J. M., Avendaño, A., Fernandez-Luis, S., Calvo, J. A., Ocio, E., Colorado, M., Bermudez, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430491/ http://dx.doi.org/10.1097/01.HS9.0000848168.22862.f7

Ejemplares similares

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
por: Sannipoli, Daniele, et al.
Publicado: (2023)

1326. Possible Predictors of Coinfection in COVID-19: Making a Difficult Diagnosis
por: Lehmann, Christopher J, et al.
Publicado: (2021)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST-ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST-ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN
por: Vallejo, C., et al.
Publicado: (2022)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

P1322: ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION (HSCT) IN PATIENTS OVER 60 YEARS. RETROSPECTIVE EXPERIENCE OF TWO SPANISH CENTERS BETWEEN 2015-2020
por: Baile González, M., et al.
Publicado: (2022)

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

P1326: HEMATOPOIETIC STEM/PROGENITOR CELLS ORIGINATING FROM EXTRAEMBRYONIC ARTERIAL VESSELS ARE THE MAJOR CONTRIBUTORS TO MOUSE FETAL LYMPHO-MYELOPOIESIS
por: Azzoni, Emanuele, et al.
Publicado: (2023)

An uncommon case of chronic myeloid leukemia with variant cytogenetics
por: Abdulla, Mohammad A., et al.
Publicado: (2018)

P1317: TIME-DEPENDENT ANALYSIS OF THE IMPACT ON EARLY CMV REACTIVATION OF HLA MISMATCH AND ACUTE GRAFT-VERSUS-HOST-DISEASE AFTER ALLO-HSCT FROM RELATED DONORS IN ACQUIRED APLASTIC ANEMIA.
por: Lin, Fan, et al.
Publicado: (2023)

P1320: INCIDENCE AND IMPACT OF COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS OVER 60 YEARS. RETROSPECTIVE EXPERIENCE OF TWO SPANISH CENTERS IN THE 2015-2020 PERIOD
por: Baile, M., et al.
Publicado: (2022)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
por: Xu, Qianwen, et al.
Publicado: (2023)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT
por: Jørgensen, Silje F., et al.
Publicado: (2021)

Clinical study of late-onset hemorrhagic cystitis after allo-HSCT without in vitro T-cell depletion
por: Yuan, Hailong, et al.
Publicado: (2022)

P986: CYTOGENETIC DIAGNOSIS WITH NEXT-GENERATION CYTOGENETICS BY OPTICAL GENOME MAPPING IN PATIENTS WITH MYELOFIBROSIS.
por: Díaz González, Á., et al.
Publicado: (2022)

P1321: INCIDENCE AND IMPACT OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PATIENTS OVER 60 YEARS OF AGE UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT). RETROSPECTIVE EXPERIENCE OF TWO SPANISH CENTERS
por: Baile, M., et al.
Publicado: (2022)

Cytogenetic profile of 1791 adult acute myeloid leukemia in India
por: Srivastava, Vivi M., et al.
Publicado: (2023)

Cytogenetics’ impact on the prognosis of acute myeloid leukemia
por: Gupta, Monika, et al.
Publicado: (2019)

Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients
por: Skaarud, K. J., et al.
Publicado: (2019)

Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia
por: Lee, Young Eun, et al.
Publicado: (2022)

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis
por: Yang, Apeng, et al.
Publicado: (2019)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ler94iia4nk8p963gnop9oaral